TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05321524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 0.1mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 0.1mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 0.1mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 1.5mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 1.5mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 1.5mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 5mg
Description: Tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCA 5mg
Description: Tablets administered orally once daily.
Study: NCT03317704

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed endurance training
Description: Speed endurance training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speed endurance training
Description: Speed endurance training
Study: NCT02855099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
Study: NCT05219240

Intervention type: OTHER
Intervention: 20Lighter Program
Description: Visceral Adiposity-Focused Anti-Obesity Telehealth Program
Study: NCT03835975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20vPnC
Description: Pneumococcal conjugate vaccine
Study: NCT02706158

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1500 mg Calcium and 1200 IU Vitamin D for 2 months
Description: 1500 mg Calcium and 1200 IU Vitamin D for 2 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balanced diet
Description: participants will get a balanced diet according to pregnancy stage
Study: NCT02159482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Alfa-2a
Study: NCT00648076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium Extended-Release Tablets 500 mg
Description: 500mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote ER® Tablets 500 mg
Description: 500mg, single dose fed
Study: NCT04485962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblasts and keratinocytes
Description: Autologous cultured fibroblasts and keratinocytes~For PR: The name  fibroblasts and keratinocytes is exactly the name of the cell product registered by our ministry of health. There is no trade or international name.
Study: NCT02545673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced linkage to care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care plus
Study: NCT01243450

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: Treatment of acne

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment of acne
Study: NCT03516318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Connections
Description: SMART Connections: Trained facilitators will deliver key informational messages and moderate online group discussions. The informational messages have been developed from key messages identified in each of the Positive Connections curriculum sessions. Each SMART Connections group will consist of approximately 15 to 20 YLHIV. Each online support group will begin with one in-person group meeting with the facilitator. During this meeting, participants meet one another and the facilitators. Facilitators will describe the intervention and set ground rules for participation. Ground rules will be discussed and accepted by the group members, but at a minimum, group members will be advised not to talk about what is discussed in the online group with people outside of the group.
Study: NCT00788554

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein procedure
Description: open surgical procedure for inguinal hernia correction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP
Description: Total Exta Peritoneal procedure for inguinal hernia correction
Study: NCT00237744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotics training for shoulder elbow.
Description: training utilizing a robot to assist with movement practice

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surface Functional Neuromuscular Stimulation
Description: training utilizing FNS to assist with movement practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole arm motor learning
Description: intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole arm motor learning
Description: intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole arm motor learning
Description: intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
Study: NCT03904472

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based CBTI
Description: Sessions comprise a range of cognitive and behavioral techniques and psychoeducation including sleep hygiene. During the intervention period the participant will complete daily online sleep diaries. Additionally, participants will be asked to complete multiple questionnaires.
Study: NCT02176889

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactospore
Description: Bacillus coagulans MTCC 5856

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01793792

Intervention type: DEVICE
Group type: OTHER
Intervention: LVIS™ and LVIS™ Jr
Description: The LVIS Device is intended for use with embolization coils for the treatment of wide neck, intracranial aneurysms.
Study: NCT00283686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Blood Pressure Control
Description: Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Blood Pressure Control
Description: Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Blood Pressure Control
Description: Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study: NCT05916508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.454% stannous fluoride
Description: Brush two times daily

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.76% sodium monofluorophosphate
Description: Brush two times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride AM and 0.76% sodium monofluorophosphate PM
Description: Brush two times daily
Study: NCT02011438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UTalk
Description: Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
Study: NCT02116465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Carbidopa immediate release tablets
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Carbidopa immediate release tablets
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Carbidopa immediate release tablets
Description: oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa Carbidopa immediate release tablets
Description: oral administration
Study: NCT03039673

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.~Riluzole treatment is part of routine care for patients with ALS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: The dose of IL-2 to be used in this study will be 2.0 million IU/day.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.~In case of intolerance, a flexible dose-reduction schedule is available.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% glucose water solution
Description: The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.~Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.
Study: NCT01775891

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pilsicainide
Description: The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pilsicainide
Description: The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: other class IC antiarrhythmic drug
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study: NCT00283686

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Blood Pressure Control
Description: Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
Study: NCT03486808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DLPFC stimulation
Description: stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DLPFC stimulation
Description: stimulating left dorsolateral prefrontal cortex with transcranial direct current stimulation for 30 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: sham stimulation over both left inferior frontal cortex and dorsolateral prefrontal cortex
Study: NCT01775891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: other class IC antiarrhythmic drug
Description: Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
Study: NCT02486224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kona Deep
Description: Subjects will receive Kona Deep post exercise
Study: NCT04611048

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Thermal QST (cold and warm detection, heat pain) with the psi method
Description: The Psi algorithm is a method using Bayesian statistics to determine not only the threshold but also the slope of the psychometric function (relationship between the intensity of a stimulus and its detection probability; Kingdom \& Prins, 2010). The algorithm selects the next stimulus intensity to be the most informative on the parameters of interest, based on the prior probability density. After each stimulation, the subject will be asked if he/she felt it (as painful) or not. Based on that answer, a posterior probability density is computed. This posterior is then used as prior for the next stimulation. The stimuli will last maximum 1 s and temperature will be kept between 0°C and 60°C.
Study: NCT02486224

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spring Water
Description: Subjects will receive Spring Water post exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sports Drink
Description: Subjects will receive Sports Drink post exercise
Study: NCT02998242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT to symptomatic bony metastatic bony site(s)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT to symptomatic bony metastatic bony site(s)
Study: NCT02585895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection once every 2 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Administered by subcutaneous injection once every 2 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
Description: Participants received apheresis for LDL-C according the their physician's prescription and local custom.
Study: NCT03181360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Best standard treatment
Study: NCT01060228

Intervention type: DRUG
Group type: OTHER
Intervention: paliperidone ER
Description: 1 tablet of 500 mg once daily on Day 1 and Day 15

Intervention type: DRUG
Group type: OTHER
Intervention: divalproex sodium ER
Description: 2 tablets of 500 mg once daily from Days 5 through 18
Study: NCT01990235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE Intervention
Description: At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
Study: NCT04365088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort 30 MG Oral Tablet
Description: After the taken a deflazacort pill once preoperatively (one hour ago), local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, the mucoperiosteal flap was repositioned by 3.0 silk sutures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Sugar pill
Study: NCT00644098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soluble fibre complex and medium chain triglycerides
Study: NCT03411655

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu Aura GainTM
Description: Time and success rate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu® Aura-ITM
Description: Time and success rate
Study: NCT03822299

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: healthy feces microbiota
Description: Suspension of healthy feces microbiota in sterile saline solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: healthy feces microbiota
Description: Suspension of healthy feces microbiota in sterile saline solution
Study: NCT00695331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Titrated Misoprostol Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Titrated Intravenous Oxytocin
Study: NCT03125304

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: acupuncture
Description: They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
Study: NCT02264067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talsaclidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03443960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 5.6 mg
Description: Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrix 30 mg
Description: Subjects randomly assigned to this treatment will swallow 1 capsules with a cup of water, and not to crush or chew it.
Study: NCT01257295

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: control: no fiber addition
Description: liquid breakfast without addition of fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: breakfast with low viscous, low gelling pectin
Description: 10g of low viscous, low gelling pectin dissolved in a liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high viscous, low gelling pectin
Description: 10g of high viscous, low gelling pectin dissolved in a liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low viscous, high gelling pectin
Description: 10g of low viscous, high gelling pectin dissolved in a liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high viscous, high gelling pectin
Description: 10g of high viscous, high gelling pectin dissolved in a liquid breakfast

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: pectin supplement
Description: 10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
Study: NCT02630667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SLOW Carbohydrate
Description: Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLOW Carbohydrate
Description: Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIUM Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MEDIUM Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAST Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FAST Carbohydrate
Description: Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response